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Oral squamous cell carcinoma (OSCC) is the seventh most common malig-
nancy and the ninth most frequent cause of cancer death in Europe.
Within Europe, Hungary has one of the highest rates of OSCC incidence
and mortality. Thus, there is an urgent need to improve early detection.
Saliva, as a readily available body fluid, became an increasingly important
substance for the detection of biomarkers for many diseases. Different
research groups have identified salivary biomarkers specific for OSCC for
different countries. In this study, saliva samples of Hungarian patients with
OSCC were studied to discover disease-specific and perhaps region-specific
biomarkers. LC-mass spectrometry (MS)/MS analysis on a linear ion trap-
Orbitrap mass spectrometer was used for qualitative and quantitative sali-
vary protein profiling. More than 500 proteins were identified from saliva
by shotgun proteomics. The up- and downregulated proteins in the saliva
of patients with OSCC highlighted the importance of protein–protein inter-
action networks involving the immune system and proteolysis in disease
development. Two potential biomarkers from our shotgun analysis and a
third candidate reported earlier by a Taiwanese group were further exam-
ined by ELISA on a larger reference set of samples. Resistin, a biomarker
reported in Taiwan but not validated in our study, highlights the necessity
of application of standardized analysis methods in different ethnic or geo-
graphical populations to identify biomarkers with sufficient specificity and
sensitivity.
The oral cavity is the most frequent site of head and
neck cancers, developing predominantly as oral cavity
squamous cell carcinomas (OSCCs) in the upper
aerodigestive epithelium [1,2]. The three major recog-
nized risk factors of OSCC are tobacco consumption,
alcohol consumption, and poor oral hygiene [3–5].
OSCC mortality rates reflect the different consumption
patterns of alcohol and tobacco in European countries
[6]. Annually, more than 300 000 new patients are
diagnosed with OSCC worldwide. The disease is asso-
ciated with poor prognosis and high mortality mainly
due to late diagnosis because of the lack of reliable
early diagnostic markers [7]. Mortality rate from
OSCC is about 10-fold higher for men than for
women. However, female OSCC incidence increased
dramatically in the last decade. In addition, a rising
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tendency was observed in younger patient cohorts [8].
In contrast to other European countries where the
mortality rates of OSCC started to decline, unfavor-
able incidence and mortality figures remained exceed-
ingly high in Hungary since the 1970s representing a
major public health challenge [9].
Development of cancer diagnostic tools with suffi-
ciently high sensitivity and specificity is required to
enable early detection of OSCC [10]. Recent treatment
strategies of patients with OSCC are based on tradi-
tional stage-predicting indices and histological grading
[11]. Unfortunately, these predictors are relatively sub-
jective and unreliable because tumors with the same
staging and grading may respond to therapy differ-
ently. Thus, improving the diagnostic methods is
required. A potential way of improving our diagnostic
tools is to perform in-depth salivary analyses to dis-
cover and to assess biochemical and immunological
markers in the saliva for early oral cancer diagnosis
[12,13]. Biomarkers identified in the last decades in
biological fluids can be linked to carcinogenesis and
may serve as prognostic factors and saliva is a new
clinical biomarker source that can be easily collected
by noninvasive means [14–18]. As there is direct con-
tact between saliva and the oral lesion(s), disease-
related concentration changes of saliva ingredients
may provide as good or better clues than serum sam-
ples [19]. More than 3700 salivary proteins have been
identified by several research groups [20,21]. Many
proteins were declared potential salivary biomarkers of
OSCC in different countries [22–24]. In this study, we
present a two-stage approach for the discovery of can-
didate OSCC-specific salivary biomarkers in the Hun-
garian population. LC-mass spectrometry (MS)/MS
analysis using ultraperformance liquid chromatogra-
phy (UPLC) coupled to a linear ion trap-Orbitrap
hybrid tandem mass spectrometer was applied for
qualitative and quantitative salivary protein profiling.
Selected proteins, based on the shotgun analysis of a
few randomly selected samples, were further investi-
gated by ELISA on a reference set of samples.
Materials and methods
Patients and saliva collection
Donor enrollment, sample collection, and processing con-
formed to the principles of the Helsinki Declaration. Ethi-
cal approval was obtained from the University of Debrecen
Ethics Committee (No. 3385-2011), and all subjects pro-
vided written informed consent. Clinical examinations were
performed by dental surgeons from the Faculty of Den-
tistry, University of Debrecen. Adult patients (> 18 years)
with histology-proven OSCC were recruited into the study.
Saliva samples were collected before starting any antitumor
therapy. Age-matched controls (MCTL) were consecutive
patients and young controls (YCTL) were medical students
admitted to the Faculty of Dentistry for regular dental
checkup. Exclusion criteria included children (≤ 18 years),
pregnancy and breast-feeding, diabetes mellitus, human
papillomavirus infection, human immunodeficiency virus
infection, autoimmune and immunodeficiency disorders,
and cancer other than OSCC.
Unstimulated saliva samples were collected from 43
donors between 9 a.m. and 11 a.m. at the Faculty of Den-
tistry, University of Debrecen (collection between May 9,
2013, and February 29, 2016). The test set contained three
randomly selected samples from patients with OSCC and
controls for proteomics analysis, whereas the reference set
contained samples from 20 patients with OSCC (mean age:
57 years), six YCTL (mean age: 24.5 years), and 11 MCTL
(mean age: 59 years) for biomarker verification. Saliva sam-
ples were kept on ice during collection and were filtered
using Millipore SLSV025LS 5-lm-pore-size syringe filters
(Merck, Billerica, MA, USA). The filtered saliva was ali-
quoted and immediately placed at 70 °C until further use.
Sample preparation for mass spectrometry
Filtered saliva was dried in SpeedVac and redissolved in
25 mM pH 8.5 ammonium bicarbonate buffer. Total pro-
tein concentration of salivary samples was measured using
the Bradford method [25]. Following denaturation with 8 M
urea, all samples were reduced with 10 mM dithiothreitol
(Bio-Rad, Hercules, CA, USA) in ammonium bicarbonate
buffer. Then, samples were alkylated with 20 mM iodoac-
etamide (Bio-Rad) in ammonium bicarbonate buffer and
diluted with 25 mM ammonium bicarbonate (Sigma, St.
Louis, MO, USA) to reduce the urea concentration to 1 M.
Each sample was digested by MS-grade modified trypsin
(AB Sciex, Framingham, MA, USA) in 1 : 25 enzyme-to-
protein ratio (w/w) at 37 °C overnight. The digested sam-
ples were dried in SpeedVac and redissolved in 0.1% formic
acid. The digests were desalted on Pierce C18 Tips (Thermo
Scientific, West Palm Beach, FL, USA), and the eluates
were dried and stored at 70 °C until MS analysis.
Mass spectrometry analysis
Tryptic digests representing 2 lg total protein were ana-
lyzed by LC-MS/MS using a Waters nanoACQUITY
UPLC Online coupled to a linear ion trap-Orbitrap hybrid
tandem mass spectrometer (Orbitrap Elite; Thermo Scien-
tific) operating in positive ion mode. After trapping at 3%
B (Waters Symmetry C18 180 lm 9 20 mm column, 5 lm
particle size, 100 A pore size; flow rate: 10 lLmin1), pep-
tides were fractionated using a linear gradient of 3–40% B
in 100 min (Waters BEH C18 75 lm 9 250 mm column,
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1.7 lm particle size, 300 A pore size; solvent A: 0.1% for-
mic acid/water; solvent B: 0.1% formic acid/5% dimethyl
sulfoxide/acetonitrile; flow rate: 400 nLmin1). Data acqui-
sition was carried out in a data-dependent fashion, and the
10 most abundant, multiply charged ions were selected
from each MS survey (m/z: 380–1600; resolution: 60 000,
acquired in profile mode) for MS/MS analyses. CID analy-
ses were performed in the linear ion trap (normalized colli-
sion energy: 35). Dynamic exclusion was enabled (exclusion
time: 30 s).
Protein identification
Peak lists generated from the MS/MS data by the ‘PAVA’
software [26] were searched against the human subset of
the UniProt database (downloaded on June 10, 2014;
136 245 target sequences concatenated with a randomized
sequence for each entry) using the PROTEINPROSPECTOR
search engine (v.5.10.9.). Search parameters: enzyme: tryp-
sin with maximum 1 missed cleavage site; fixed modifica-
tion: carbamidomethyl (Cys); variable modifications:
acetylation (protein N terminus), oxidation (Met), and
pyroglutamic acid formation (N-terminal Gln) allowing up
to two variable modifications per peptide; and mass accu-
racy: 5 p.p.m. and 0.6 Da for precursor and fragment ions
(both monoisotopic), respectively. The following acceptance
criteria were applied: score > 22 and 15, and E-value < 0.01
and 0.05 for protein and peptide identifications, respec-
tively. The false-positive rates of the identified proteins and
peptides were < 1%. Relative abundance of individual pro-
teins was estimated by spectral counting: The number of
identifications per protein (PSMs) was normalized to the
total number of identifications, and then, these relative
spectral counts were compared across the different samples.
Functional analyses were performed in the case of pro-
teins with at least three unique peptide identifications. For
the calculation of the OSCC/control ratio, the proteins
which were identified with at least three unique peptides in
at least two of three samples in either the control or the
OSCC group were considered.
Validation of the candidate biomarkers using
ELISA
All saliva samples from patients with OSCC and controls
were analyzed in duplicate with quantitative ELISA. The
ELISA kit for heparin cofactor 2 (Cat. number:
LS-F13221) was purchased from LifeSpan Biosciences
(Seattle, WA, USA), for resistin (Cat. number: KHP0051)
from Thermo Fisher Scientific (West Palm Beach, FL,
USA), and for complement C5 (Cat. number: ab125963)
from Abcam (Branford, CT, USA). The concentration of
the studied proteins in saliva was measured by the sand-
wich ELISA method according to the instruction provided
by the vendor of each kit. Absorbance was measured at
450 nm, and concentrations were calculated based on the
recorded 7-point calibration curves.
First, the variation coefficient of the parallel measure-
ments was calculated and those data having more than 25
CV % value were excluded from statistical analysis.
Bioinformatics
The cluster analysis was carried out with Cluster 3.0
(http://cluster2.software.informer.com/) using the C CLUS-
TERING LIBRARY version 1.52, and the heat map was created
with JAVA TREEVIEW version 1.1.6r4 [27].
The protein–protein interaction network of salivary pro-
teins was generated using STRING version 10.5 [28,29] apply-
ing default settings and medium stringency. After the
generation of networks, the enriched gene ontology (GO)
terms provided by the software were also examined.
The statistical analysis of ELISA data was performed
using the Mann–Whitney U-test and the two-sample t-test
to compare the protein concentrations between groups. The
data were considered significantly different where the P
value was < 0.05.
Results and Discussion
Demographic and clinical characteristics of
patients with OSCC
Among the included 17 patients, 13 were males and 4
females between the age of 44 and 73 years. The
tumor developed in the tongue (T) in six cases and in
the floor of the mouth (F) in four cases, and in three
cases, it was detected in the gingival (G) region. In
four cases, the tumor development showed multiple
localization, and in two patients, the tumor developed
in the T and either in the F or in the G region, while
in another two patients, the tumor development was
detected in the T, in the F, and also in the G region.
Eight patients were discovered in early tumor develop-
ment stage (stage I: 5; and stage II: 3), and nine
patients were diagnosed with advanced tumors (stage
III: 4; and stage IV: 5). There were six well-differen-
tiated (W), seven moderately differentiated (M), and
four poorly differentiated (P) OSCC samples
(Table 1).
Shotgun proteomics analysis of saliva samples
Three randomly selected samples from patients with
OSCC and matched controls, respectively, were sub-
jected to shotgun proteomics analysis. More than 500
proteins were identified from salivary samples. For
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protein quantification, spectral counting was used and
the ratios of OSCC : CTL protein quantities have
been determined. Detailed information of the identified
proteins is presented in Table S1.
The proteins with at least three unique sequences and
with at least twofold change value (OSCC/CTL ratio
< 0.5 or > 2) were subjected to further examination. A
cluster analysis was carried out, and a heat map was
generated to visualize the changes in protein amount in
CTL and OSCC samples (Fig. 1). Based on cluster anal-
ysis, the protein levels can discriminate the OSCC group
from the CTL group. Proteins were classified as salivary
proteins or proteins being present in saliva under nor-
mal conditions and as acute-phase proteins (Table 2).
For protein classification, the UniProt and Sys-Body-
Fluid databases were used; the latter contains more than
10 000 proteins of different body fluid proteomes [30].
In addition, some proteins were classified as salivary
proteins based on the literature data [21,31–35].
Two proteins, cytochrome c and mucin-7, were only
present in the CTL samples, and six proteins, comple-
ment factor H (CFH) and C5 (C5), corticosteroid-
binding globulin (SERPINA6), heparin cofactor 2
(SERPIND1), apolipoprotein E (APOE), and serum
paraoxonase/arylesterase 1 (PON1), were only present
in the OSCC samples (Table 3).
Functional analysis of salivary proteins
It was observed that the level of some proteins such as
apolipoproteins, components of the complement
system, proteinases, proteinase inhibitors, components of
the coagulation cascade is upregulated. This might indi-
cate a change in proteolysis most probably associated
with the interrelated coagulation cascade-complement
activation processes. At the same time, the level of
proteins having role in metabolism and host defense
was downregulated showing extensive cancer-related
changes (Table 2). For a more detailed functional anal-
ysis of the differentially expressed proteins, GO analysis
was performed; the Biological Process, Molecular Func-
tion, and Cellular Localization according to GO (http://
www.geneontology.org/) were examined. First, the net-
work of differentially expressed proteins was generated
using STRING version 10.5 [28,29], followed by GO
enrichment analysis provided by String. The network of
downregulated proteins contained 35 proteins (nodes)
and 27 possible protein–protein interactions analyzed at
medium stringency (Fig. 2A). No biological function
was enriched in the downregulated proteins in this
loosely connected network (Fig. 2B); however, seven of
35 downregulated proteins are metabolic enzymes par-
ticipating mainly in carbohydrate metabolism and 10 of
35 proteins have a role in defense. The upregulated 45
proteins show a highly interconnected protein–protein
interaction network with 400 interactions analyzed at
medium stringency (Fig. 2C). The enriched functions
indicate active regulatory mechanisms implicating the
immune system, lipid metabolism, plasminogen activa-
tion, antioxidant activity, and inhibition of enzymatic
activities (Fig. 2D). Regarding localization of up- or
downregulated proteins, all are mainly extracellular
Table 1. Demographic and clinical characteristics of patients with OSCC. In the case of each patient, the gender, age, tumor localization,
TNM classification, tumor stage, and stage of differentiation are given. M is for male and F for female. Regarding tumor localization, T is for
tongue, G is for gingiva, and F is for floor of the mouth. The W is for well-differentiated, M is for moderately differentiated, and P is for
poorly differentiated tumors.
Patient code Gender Age (year) Tumor localization TNM classification Tumor stage Stage of differentiation
1 M 73 T T2N1M0 III W
2 F 69 G T4N0M0 IV W
3 F 67 F T4N2M0 IV W
4 M 52 T; G; F T4N1M0 IV M
5 M 57 T T3N0M0 III W
6 F 59 T T1N0M0 I W
7 M 67 F T1N0M0 I W
8 F 50 T T2N0M0 II M
9 M 52 T; G T2N2M0 IV M
10 M 48 T T1N0M0 I M
11 M 64 T T2N0M0 II P
12 M 44 G T4N1M0 IV M
13 M 44 T; F T3N0M0 III M
14 M 60 F T2N0M0 II M
15 M 49 T; G; F T3N1M0 III P
16 M 47 G T1N0M0 I P
17 M 64 F T1N0M0 I P
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proteins according to GO (Fig. 2B,D), but a part of the
upregulated proteins originate from lipid particles or
platelet alpha-granules indicating the presence of a pos-
sibly cancer-induced complex process involving systemic
mechanisms.
To obtain more insights into the changes associated
with OSCC, a literature search was performed to see
which proteins have been associated with oncogenesis.
Most of the proteins were already associated with
OSCC, and 32 proteins were identified to be present in
saliva in this pathological condition.
Complement C4B (C4B), complement factor B
(CFB), complement C3, and alpha-1-antitrypsin were
shown to be associated with the risk of developing
OSCC according to a targeted proteomics study [36].
The levels of apolipoproteins A and E; PON1; inter-
alpha-trypsin inhibitor heavy chain H1, H2, and H4;
kininogen 1; protein AMBP; nucleobindin-2; SER-
PIND1; and SERPINA6 were found to be upregulated
in OSCC in shotgun proteomics experiments carried out
on saliva samples [23]. The presence of APOE was
related to the increased invasion potential of OSCC [37].
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Fig. 1. Cluster analysis and heat map of proteins identified in the CTL and OSCC groups. The relative peptide count (%), characteristic of
each sample, is shown.
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Table 2. List of proteins with at least twofold change between OSCC and CTL groups. The UniProt protein ID, the protein name, and
function are presented. The representative identification and quantification data, the number (#) of unique peptides, the sequence coverage
(%Cov), and the OSCC/CTL ratio are given in each case. Classification indicating salivary (S) or acute-phase (A) proteins is presented. The
type of sample from patients with OSCC where the protein was identified is also listed. NI denotes proteins not identified in OSCC yet.
Protein ID Protein name
# Unique
peptide %Cov
OSCC/
CTL ratio Classification Function
Type of OSCC
sample
O60218 Aldo-keto reductase
family 1 member B10
5 17 0.10 S Metabolic enzyme Salivaa [23]
P02763 Alpha-1-acid glycoprotein
1
8 37 3.14 AS Immune response, transport Saliva [16]
P01011 Alpha-1-antichymotrypsin 12 31 3.29 AS Protease inhibitor NI
P01009 Alpha-1-antitrypsin 25 62 3.70 S Protease inhibitor Saliva [36]
P04217 Alpha-1B-glycoprotein 12 39 3.25 S Immune response Saliva [16]
P02765 Alpha-2-HS-glycoprotein 7 26 2.70 AS Protease inhibitor, immune
response, transport
NI
P01023 Alpha-2-macroglobulin 54 51 2.16 S Protease inhibitor NI
P04745 Alpha-amylase 1 42 83 0.21 S Metabolic enzyme Saliva [14]
P01019 Angiotensinogen 7 18 8.50 AS Renin–angiotensin system NI
P01008 Antithrombin III 7 22 2.08 AS Protease inhibitor, blood
coagulation
NI
P02647 Apolipoprotein A-I 24 69 2.14 S Lipid metabolism Saliva [23]
P02652 Apolipoprotein A-II 7 67 3.85 S Lipid metabolism Saliva [23]
P06727 Apolipoprotein A-IV 5 16 3.55 S Lipid metabolism Saliva [23]
P04114 Apolipoprotein B-100 42 13 8.12 S Lipid metabolism NI
P02649 APOE 4 18 Only in OSCC S Lipid metabolism Saliva [23]
P17213 Bactericidal permeability-
increasing protein
4 12 0.24 S Immune response NI
P02749 Beta-2-glycoprotein 1 12 44 3.02 S Lipid metabolism, blood
coagulation
Saliva [22]
P61769 Beta-2-microglobulin 5 57 0.46 S Immune response NI
Q96DR5 BPI fold-containing
family A member 2
11 41 0.49 S Immune response, defense NI
Q14CN2 Calcium-activated
chloride channel
regulator 4
5 8 0.23 S Transport NI
P27482 Calmodulin-like protein 3 6 64 0.37 S Metal binding, chaperone NI
P27797 Calreticulin 4 19 0.37 S Chaperone NI
P00915 Carbonic anhydrase 1 6 34 8.55 S Metabolic enzyme, acid–
base balance
Saliva [22]
P00450 Ceruloplasmin 27 37 3.65 AS Metal binding Blood [39]
O00299 Chloride intracellular
channel protein 1
7 34 0.31 S Transport, cell cycle
regulation
NI
P01024 Complement C3 84 61 2.77 AS Immune response Saliva [36]
P0C0L5 Complement C4-B 32 25 6.69 AS Immune response Saliva [36]
P01031 Complement C5 7 5 Only in OSCC AS Immune response NI
B4E1Z4 CFB 22 22 5.44 AS Immune response Saliva [36]
P08603 CFH 21 22 Only in OSCC AS Immune response NI
P05156 Complement factor I 3 7 6.42 AS Immune response NI
P22528 Cornifin-B 6 79 0.45 S Cornification NI
P08185 Corticosteroid-binding
globulin
4 15 Only in OSCC AS Protease inhibitor Saliva [23]
P04080 Cystatin-B 6 86 0.39 S Protease inhibitor NI
P01034 Cystatin-C 7 43 0.33 S Protease inhibitor NI
P09228 Cystatin-SA 13 69 0.35 S Protease inhibitor Saliva [14]
P99999 Cytochrome c 4 32 0.00 A Electron transport chain,
apoptosis
Tissue [53]
Q02413 Desmoglein-1 8 12 0.40 S Desmosome component NI
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Table 2. (Continued).
Protein ID Protein name
# Unique
peptide %Cov
OSCC/
CTL ratio Classification Function
Type of OSCC
sample
P61916 Epididymal secretory
protein E1
4 33 0.30 S Lipid metabolism,
cholesterol transport
NI
Q01469 Fatty acid-binding
protein, epidermal
12 79 0.49 S Lipid metabolism Salivaa [23]
P02671 Fibrinogen alpha chain 11 13 2.67 AS Blood coagulation Blood [40]
P02675 Fibrinogen beta chain 20 49 2.91 AS Blood coagulation Blood [40]
P02679 Fibrinogen gamma chain 18 48 2.43 AS Blood coagulation Blood [40]
B7ZLE5 FN1 protein 24 17 5.73 S Cell adhesion Tissue [42]
P00738 Haptoglobin 29 67 2.61 AS Heme binding Blood [38]
P69905 Hemoglobin subunit
alpha
11 92 3.37 S Oxygen transport Salivaa [23]
P68871 Hemoglobin subunit
beta
17 94 4.41 S Oxygen transport Salivaa [23]
P02790 Hemopexin 20 52 2.41 AS Heme binding Saliva [16, 22]
P05546 Heparin cofactor 2 8 17 Only in OSCC A Blood coagulation Saliva [23]
Q9Y6R7 IgGFc-binding protein 52 17 0.49 S Immune response NI
P11215 Integrin alpha-M 6 9 2.01 S Immune response Tissue [41]
P19827 Inter-alpha-trypsin
inhibitor heavy chain H1
8 14 3.76 S Protease inhibitor Saliva [23]
P19823 Inter-alpha-trypsin
inhibitor heavy chain H2
10 18 11.23 S Protease inhibitor Saliva [23]
Q14624 Inter-alpha-trypsin
inhibitor heavy chain H4
13 22 5.33 S Protease inhibitor Saliva [23]
P02538 Keratin, type II
cytoskeletal 6A
21 39 0.44 S Cytoskeleton NI
P01042 Kininogen-1 11 18 2.89 S Protease inhibitor, blood
coagulation
Saliva [23]
P61626 Lysozyme C 7 54 0.47 S Host defense NI
P40926 Malate dehydrogenase,
mitochondrial
4 17 0.37 S Metabolic enzyme NI
Q8TAX7 Mucin-7 4 12 0.00 S Host defense NI
P80303 Nucleobindin-2 8 26 0.32 S Metal binding Saliva [23]
Q6UX06 Olfactomedin-4 7 20 0.47 S Cell adhesion NI
P36871 Phosphoglucomutase-1 6 13 0.08 S Metabolic enzyme NI
Q96G03 Phosphoglucomutase-2 5 11 0.40 S Metabolic enzyme NI
P00558 Phosphoglycerate kinase
1
10 33 0.44 S Metabolic enzyme Saliva [22]
P36955 Pigment epithelium-
derived factor
4 12 7.17 S Tumor development,
angiogenesis
NI
P05155 Plasma protease C1
inhibitor
8 21 5.95 S Protease inhibitor, blood
coagulation
NI
P00747 Plasminogen 9 17 5.11 AS Blood coagulation NI
P02760 Protein AMBP 6 23 5.41 S Protease inhibitor, host
defense
Saliva [23]
O60888 Protein CutA 3 33 0.43 S Metal binding, enzyme
binding
NI
P02753 Retinol-binding protein 4 5 24 2.54 S Protease inhibitor, host
defense
Blood [38]
Q9NQ38 Serine protease inhibitor
Kazal-type 5
11 13 0.32 S Lipid metabolism NI
P36952 Serpin B5 4 14 2.63 S Tumor suppressor Blood [12]
P02768 Serum albumin 71 84 2.53 S Transport Saliva [22]
P27169 Serum paraoxonase/
arylesterase 1
9 37 Only in OSCC A Detoxification Saliva [23]
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The alpha-1-acid glycoprotein, alpha-1B glycopro-
tein, alpha-amylase, beta-2-glycoprotein, carbonic
anhydrase 1, cystatin-SA, hemopexin, phosphoglycer-
ate kinase, and serum albumin were identified as
potential salivary markers of OSCC [14,16,22].
Some of the proteins found to be differentially
expressed in our study, such as fibrinogen alpha, beta,
and gamma chains, haptoglobin, SERPINB5, retinol-
binding protein 4, and ceruloplasmin, were shown to
be plasma markers of OSCC, while the presence of
integrin alpha-M and fibronectin FN1 was demon-
strated in the OSCC tissue [12,38–42].
In the case of 36 proteins, no association with
OSCC was found so far (Table 2). Angiotensinogen
and plasminogen themselves were not found to be
associated with OSCC, but the plasminogen activator
system was shown to be a predictive marker for early
OSCC, and by bioinformatics analysis, the angioten-
sin-converting enzymes were associated with malig-
nant epithelial neoplasia characteristic of OSCC
[43,44]. In the case of six proteins, not the protein
from our list, but another protein from the same
family was already demonstrated to be differentially
expressed in OSCC (Table 2). In the case of SER-
PINB5, there are contradictory data; in our study,
the level of SERPINB5 was found to be elevated in
OSCC; however, the SERPINB5 and different forms
of SERPINS from clade B were found by other
groups to be downregulated in OSCC on mRNA
level and higher SERPINB5 levels were found to
Table 2. (Continued).
Protein ID Protein name
# Unique
peptide %Cov
OSCC/
CTL ratio Classification Function
Type of OSCC
sample
P35326 Small proline-rich protein
2A
6 79 0.29 S Cornification Salivaa [23]
Q6UWP8 Suprabasin 12 33 0.05 S Cell proliferation NI
P62328 Thymosin beta-4 5 64 0.42 S Actin binding, cell
proliferation
NI
O60235 Transmembrane
protease serine 11D
3 10 0.20 S Protease, host defense NI
P68363 Tubulin alpha-1B chain 4 12 0.40 S Microtubule component Salivaa [23]
O75083 WD repeat-containing
protein 1
7 19 0.13 S Cell migration NI
aIndicates that not the protein itself, but another close family member of it was already found in OSCC.
Table 3. Proteins identified only in the OSCC or CTL group.
Protein IDa Protein name Gene name Function Presence Reference to previous studies
P02649 APOE APOE Lipid metabolism Only OSCC Identified in saliva of patients with OSCC [23]
P01031 Complement C5 C5 Innate immune
response, complement
component
Only OSCC Not identified in cancer yet
P08603 CFH CFH Innate immune
response, complement
component
Only OSCC Identified in other forms of cancer but not in
OSCC [49,50]
P08185 Corticosteroid-
binding globulin
SERPINA6 Protease inhibitor Only OSCC Identified in saliva of patients with OSCC [23]
P05546 Heparin cofactor 2 SERPIND1 Blood coagulation Only OSCC Identified in saliva of patients with OSCC [23]
P27169 Serum
paraoxonase
/arylesterase 1
PON1 Detoxification Only OSCC Identified in saliva of patients with OSCC [23]
P99999 Cytochrome c CYCS Electron transport chain,
its release from
mitochondria initiates
apoptosis
Only Ctrl Its release was inhibited in OSCC [53]
Q8TAX7 Mucin-7 MUC7 Antibacterial activity,
host defense
Only Ctrl Not identified in cancer yet
aBased on http://www.uniprot.org/.
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correlate with better prognosis of patients with oral
cancer [45,46].
Plasma protease C1 inhibitor (SERPING1),
antithrombin III, and fibronectin were found to play a
role in carcinogenesis, but their implication in oral
cancer, especially in OSCC, has not been demonstrated
yet [47,48]. The CFH was previously identified in lung
adenocarcinoma and cutaneous squamous cell
Pathway ID Pathway description Observedgene count
False
discovery
rate
I. Localization
GO.0070062 Extracellular region part 24 3.56e–09
GO.0005576 Extracellular region 26 1.69e–09
GO.0031988 Extracellular exosome 25 1.11e–12
GO.0044421 Membrane-boundedvesicle 25 1.09e–10
A B
Pathway
ID Pathway description
Observed
gene count
False
discovery
rate
I. Biological process
GO.0002697 Regulation of immune effector process 10 9.91e–07
GO.0031639 Plasminogen activation 4 9.91e–07
GO.0034370 Triglyceride-rich lipoproteinparticle remodeling 4 9.91e–07
GO.0034374 Low-density lipoproteinparticle remodeling 4 9.91e–07
GO.0019216 Regulation of lipid metabolic process 8 9.53e–06
II. Molecular Function
GO.0005319 Lipid transporter activity 6 9.06e–06
GO.0017127 Cholesterol transporteractivity 5 7.23e–08
GO.0016209 Antioxidant activity 5 6.64e–05
GO.0004857 Enzyme inhibitor activity 19 4.76e–20
GO.0004867 Serine-type endopeptidaseinhibitor activity 14 4.76e–20
III. Localization
GO.0070062 Extracellular exosome 43 9.48e–34
GO.0034364 High-density lipoproteinparticle 6 8.65e–10
GO.0005577 Fibrinogen complex 4 8.3e–08
GO.0005576 Extracellular region 43 7.68e–26
GO.0031091 Platelet alpha-granule 10 6.88e–15
C D
Fig. 2. The protein–protein interaction network and functional classification of up- and downregulated proteins in OSCC. The network of
downregulated (A) and upregulated (C) proteins in OSCC displayed by String 10.4 using default settings and medium stringency. Each node
represents a protein and the edges represent protein–protein interactions based on different levels of evidence collected by String. The
enrichment table of GO terms calculated by String in the case of downregulated (B) and upregulated (D) proteins is shown indicating the
number of the proteins belonging to each term and the false discovery rate calculated by String.
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carcinoma, but not in OSCC [49,50], and apoB100 was
found in serum of patients with head and neck squa-
mous cell carcinoma [51]. No data were found on the
presence of complement C5 and mucin-7 in cancer;
however, other components of the complement system
and other forms of mucins were all identified in differ-
ent forms of cancer and in OSCC as well [36,52].
As for the involvement of cytochrome c, it was
shown that the HIF-1a-dependent suppression of
hypoxia-induced apoptosis in OSCC happens through
the inhibition of cytochrome c release [53].
Examination of the level of selected proteins by
ELISA
Many of the studies published in the scientific litera-
ture are based on shotgun proteomics experiments.
Only few of the proteins listed in Table 2 were verified
or validated either using SRM-based targeted or anti-
body-based methods. Considering the proteins present
only in OSCC based on our shotgun experiments, the
data presented in the literature, and the availability of
antibodies, SERPIND1 and C5 were selected for fur-
ther studies. To test the utility of potential biomarkers
identified in Asia for a European population, resistin
reported to be a potential biomarker for OSCC in Tai-
wan [23] was also selected.
The concentrations of C5, SERPIND1, and resistin
were examined in the saliva of patients with OSCC,
MCTL, and YCTL using quantitative sandwich
ELISA kits (Fig. 3). In the case of C5, the difference
was significant but only when YCTL and patients with
OSCC or YCTL and MCTL were compared, indicat-
ing that the level of C5 was age-dependent or it was
influenced by other factors. One such factor can be the
inflammatory status related to poor oral hygiene often
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Fig. 3. Examination of potential salivary biomarkers using ELISA. The concentration of SERPIND1 (A), resistin (B), and complement C5 (C)
proteins in the saliva samples collected from patients with OSCC, YCTL, and MCTL. The P value is indicated; * refers to P < 0.05.
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observed in the middle-aged and elderly population in
Hungary [54]. This means that despite the differential
expression of C5 in the OSCC group, the level of C5
does not discriminate between the target MCTL and
the diseased group, and hence, it cannot be used as a
biomarker for OSCC.
In the case of resistin and SERPIND1, no signifi-
cant differences were found between the groups. Resis-
tin was not up- or downregulated according to our
shotgun experiments and did not show significant dif-
ferences in the ELISA experiments either. In the case
of SERPIND1, one possible explanation of the dis-
agreement between the shotgun proteomics and ELISA
data can be that the low number of samples (three for
each group) tested by shotgun proteomics and the high
individual variation of the saliva samples collected
from the patients may lead to false-positive results.
This outcome highlights the importance of validation
of the shotgun proteomics data on larger patient
cohorts to decrease the false positivity of biomarker
identifications. In a two-stage experimental approach,
starting with a shotgun proteomics experiment, the
level of resistin was found to be significantly higher in
the saliva samples of patients with OSCC compared to
controls. However, following ELISAs showed that the
median values in the OSCC group were only slightly
elevated compared to the control group [23]. In the
same study, SERPIND1 was not validated but was
shown to be upregulated in the saliva samples of
patients with OSCC. In our study, a similar experi-
mental setup was applied; in the shotgun experiment,
the level of SERPIND1 was higher but the level of
resistin did not change markedly in the OSCC group,
and the validation of SERPIND1 and resistin shows
that none of them turned to be useful potential
biomarkers. The fact that resistin was identified as a
biomarker for OSCC in Taiwan but not in Hungary
gives further evidence for the importance of regional
studies highlighted in our previous work [55].
Conclusions
Global analysis of salivary samples from patients
with OSCC and controls contributes to the better
understanding of the disease, including the interaction
of tumor cells with their environment and the influ-
ence of cancer lesion on salivary protein ecology.
Salivary proteins, characterizing patients with OSCC
in this study, highlighted the importance of networks
involving the immune system and proteolysis in this
disease. Six proteins were only detected in OSCC
samples by proteomics analyses and two of them
were further examined using ELISA, but none of the
proteins turned to be a potential biomarker in OSCC
in our study group. The fact that resistin was shown
to be a possible biomarker in Taiwan but not in our
study highlights the importance of regional or popu-
lation-tailored studies.
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